{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:12:21Z","timestamp":1790809941698,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.pt.2014.04.003","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T01:19:04Z","timestamp":1398475144000},"page":"289-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":308,"title":["Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects"],"prefix":"10.1016","volume":"30","author":[{"given":"Stephen","family":"Patterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wyllie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2014.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1172\/JCI33945","article-title":"Kinetoplastids: related protozoan pathogens, different diseases","volume":"118","author":"Stuart","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pt.2014.04.003_bib0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1098\/rstb.2001.1040","article-title":"Metabolic pathway analysis in trypanosomes and malaria parasites","volume":"357","author":"Fairlamb","year":"2002","journal-title":"Philos. Trans. R. Soc. Lond. B: Biol. Sci."},{"key":"10.1016\/j.pt.2014.04.003_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bcp.2005.10.043","article-title":"Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line","volume":"71","author":"Wyllie","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pt.2014.04.003_bib0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pt.2014.04.003_bib0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CIA.S3787","article-title":"Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease","volume":"4","author":"Truong","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.pt.2014.04.003_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2165\/00003495-198530030-00002","article-title":"Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders","volume":"30","author":"Sorkin","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.pt.2014.04.003_bib0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003495-198020050-00002","article-title":"Flunitrazepam: a review of its pharmacological properties and therapeutic use","volume":"20","author":"Mattila","year":"1980","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.pt.2014.04.003_bib0040","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s00436-002-0754-9","article-title":"Nitroheterocyclic drugs with broad spectrum activity","volume":"90","author":"Raether","year":"2003","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.pt.2014.04.003_bib0045","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2174\/156802611796575894","article-title":"Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives","volume":"11","author":"Wilkinson","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0050","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.7.7.953","article-title":"Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections","volume":"7","author":"Hemphill","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.pt.2014.04.003_bib0055","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.00909-08","article-title":"Giardia, Entamoeba and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases)","volume":"53","author":"Pal","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2014.04.003_bib0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/i360071a002","article-title":"The nitroaromatic group in drug design. Pharmacology and toxicology (for nonpharmacologists)","volume":"18","author":"Straus","year":"1979","journal-title":"Ind. Eng. Chem. Prod. Res. Dev."},{"key":"10.1016\/j.pt.2014.04.003_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pharmtox-010510-100514","article-title":"Bioactivation of drugs: risk and drug design","volume":"51","author":"Walsh","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pt.2014.04.003_bib0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/clinids\/3.3.479","article-title":"Chloramphenicol: a review of its use in clinical practice","volume":"3","author":"Feder","year":"1981","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.pt.2014.04.003_bib0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0006-2952(86)90565-4","article-title":"The biological properties of reduced nitroheterocycles and possible underlying biochemical mechanisms","volume":"35","author":"Whitmore","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pt.2014.04.003_bib0080","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.chembiol.2012.05.017","article-title":"ALDH2 mediates 5-nitrofuran activity in multiple species","volume":"19","author":"Zhou","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.pt.2014.04.003_bib0085","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1016\/j.bmcl.2013.08.029","article-title":"Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters","volume":"23","author":"Shultz","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pt.2014.04.003_bib0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cmdc.200700139","article-title":"Lessons learnt from assembling screening libraries for drug discovery for neglected diseases","volume":"3","author":"Brenk","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pt.2014.04.003_bib0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev.mi.27.100173.001533","article-title":"Chemotherapeutic properties of heterocyclic compounds: monocyclic compounds with five-membered rings","volume":"27","author":"Grunberg","year":"1973","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.pt.2014.04.003_bib0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-4894(62)90046-2","article-title":"Chemotherapy and chemoprophylaxis of African trypanosomiasis","volume":"12","author":"Williamson","year":"1962","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.pt.2014.04.003_bib0105","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0079-6468(08)70446-6","article-title":"The nitrofurans","volume":"5","author":"Muira","year":"1967","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0110","series-title":"The African Trypanosomiases","first-page":"125","article-title":"Review of chemotherapeutic and chemoprophylactic agents","author":"Williamson","year":"1970"},{"key":"10.1016\/j.pt.2014.04.003_bib0115","first-page":"30","article-title":"Chemotherapy of experimental Chagas disease with nitrofuran compounds","volume":"38","author":"Packchanian","year":"1952","journal-title":"J. Parasitol."},{"key":"10.1016\/j.pt.2014.04.003_bib0120","first-page":"13","article-title":"Chemotherapy of experimental Chagas disease with nitrofuran compounds","volume":"7","author":"Packchanian","year":"1957","journal-title":"Antibiotics Chemotherapy"},{"key":"10.1016\/j.pt.2014.04.003_bib0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/00034983.1988.11812275","article-title":"The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enrietti in vitro and in vivo","volume":"82","author":"Neal","year":"1988","journal-title":"Annu. Rev. Trop. Med. Parasitol."},{"key":"10.1016\/j.pt.2014.04.003_bib0130","first-page":"475","article-title":"Clinical-trials with nifurtimox in African trypanosomiasis","volume":"57","author":"Janssens","year":"1977","journal-title":"Ann. Soc. Belg. Med. Trop."},{"key":"10.1016\/j.pt.2014.04.003_bib0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1472-8206.2003.00167.x","article-title":"Treatment perspectives for human African trypanosomiasis","volume":"17","author":"Bouteille","year":"2003","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.pt.2014.04.003_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(08)60410-8","article-title":"The treatment of human African trypanosomiasis","volume":"33","author":"P\u00e9pin","year":"1994","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.pt.2014.04.003_bib0145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0035-9203(92)90298-Q","article-title":"High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire","volume":"86","author":"P\u00e9pin","year":"1992","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2014.04.003_bib0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox\u2013eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2014.04.003_bib0155","first-page":"123","article-title":"Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country","volume":"24","author":"Carrilero","year":"2011","journal-title":"Rev. Esp. Quimioter."},{"key":"10.1016\/j.pt.2014.04.003_bib0160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1155\/2009\/463575","article-title":"Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole","volume":"2009","author":"Buschini","year":"2009","journal-title":"J. Parasitol. Res."},{"key":"10.1016\/j.pt.2014.04.003_bib0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1590\/S0074-02761991000200008","article-title":"Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy","volume":"86","author":"Andrade","year":"1991","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.pt.2014.04.003_bib0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1590\/S0074-02762009000900042","article-title":"The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease","volume":"1","author":"Marin-Neto","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.pt.2014.04.003_bib0175","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1021\/jm301215e","article-title":"A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro","volume":"56","author":"Zhou","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0180","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1016\/j.bmc.2013.08.022","article-title":"Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagistic agents","volume":"21","author":"Papadopoulou","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0185","doi-asserted-by":"crossref","first-page":"28466","DOI":"10.1074\/jbc.M113.494781","article-title":"An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs","volume":"288","author":"Voak","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0190","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole \u2013 a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2014.04.003_bib0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MPH.0b013e3181f47061","article-title":"A phase 1 study of nifurtimox in patients with relapsed\/refractory neuroblastoma","volume":"33","author":"Saulnier","year":"2011","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.pt.2014.04.003_bib0200","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/ml300114c","article-title":"Drug repurposing and the medicinal chemist","volume":"3","author":"Aub\u00e9","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.pt.2014.04.003_bib0205","doi-asserted-by":"crossref","first-page":"119re1","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2014.04.003_bib0210","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1371\/journal.pctr.0010039","article-title":"Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda","volume":"1","author":"Priotto","year":"2006","journal-title":"PLoS Clin. Trials"},{"key":"10.1016\/j.pt.2014.04.003_bib0215","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-3156.1998.00291.x","article-title":"Megazol combined with suramin: a chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice","volume":"3","author":"Enanga","year":"1998","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2014.04.003_bib0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-3156.2003.01154.x","article-title":"Megazol combined with suramin improves a new diagnosis index of the early meningo-encephalitic phase of experimental African trypanosomiasis","volume":"9","author":"Darsaud","year":"2004","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.pt.2014.04.003_bib0225","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1128\/AAC.47.10.3368-3370.2003","article-title":"Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage","volume":"47","author":"Enanga","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2014.04.003_bib0230","first-page":"739","article-title":"Chemotherapeutically active nitro-compounds. 4. 5-Nitroimidazoles (Part III)","volume":"28","author":"Winkelmann","year":"1978","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pt.2014.04.003_bib0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/00034983.1983.11811668","article-title":"The activity of Fexinidazole (Hoe-239) against experimental infections with Trypanosoma cruzi, Trichomonads and Entamoeba histolytica","volume":"77","author":"Raether","year":"1983","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.pt.2014.04.003_bib0240","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: a potential new drug candidate for Chagas disease","volume":"6","author":"Bahia","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2014.04.003_bib0245","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis","volume":"57","author":"Patterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2014.04.003_bib0250","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benzidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"5","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2014.04.003_bib0260","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.pt.2014.04.003_bib0265","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/cmdc.200900499","article-title":"The tunable functionality of \u03b1,\u03b2-unsaturated carbonyl compounds enables their differential application in biological systems","volume":"5","author":"Amslinger","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pt.2014.04.003_bib0270","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10771","article-title":"High-throughput decoding of antitrypanosomal drug efficacy and resistance","volume":"482","author":"Alsford","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pt.2014.04.003_bib0275","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/ja00292a053","article-title":"Electrophilic intermediate in the reactions of a 2-(hydroxylamino)imidazole. A model for biological effects of reduced nitroimidazoles","volume":"107","author":"McClelland","year":"1985","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.pt.2014.04.003_bib0280","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1139\/v89-331","article-title":"4,5-Dihydro-4,5-dihydroxyimidazoles as products of the reduction of 2-nitroimidazoles. HPLC assay and demonstration of equilibrium transfer of glyoxal to guanine","volume":"67","author":"Panicucci","year":"1989","journal-title":"Can. J. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0285","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1021\/ja00248a028","article-title":"Products of the reductions of 2-nitroimidazoles","volume":"109","author":"McClelland","year":"1987","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.pt.2014.04.003_bib0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1515\/DMDI.2008.23.1-2.125","article-title":"Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems \u2013 role in ageing and disease","volume":"23","author":"Thornalley","year":"2008","journal-title":"Drug Metabol. Drug Interact."},{"key":"10.1016\/j.pt.2014.04.003_bib0295","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.00332-10","article-title":"Cross-resistance to nitro-drugs and implications for the treatment of human African trypanosomiasis","volume":"54","author":"Sokolova","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2014.04.003_bib0300","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01788-12","article-title":"Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation","volume":"57","author":"Wyllie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2014.04.003_bib0305","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pt.2014.04.003_bib0310","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1073\/pnas.0508392103","article-title":"Identification of a nitro-imidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis","volume":"103","author":"Manjunatha","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.pt.2014.04.003_bib0315","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1476-5381.2010.01040.x","article-title":"Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver","volume":"162","author":"Dogra","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pt.2014.04.003_bib0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cib.2.3.7926","article-title":"The mechanism of action of PA-824","volume":"2","author":"Manjunatha","year":"2009","journal-title":"Commun. Integr. Biol."},{"key":"10.1016\/j.pt.2014.04.003_bib0325","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pt.2014.04.003_bib0330","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/infdis\/jis331","article-title":"Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population","volume":"206","author":"Mejia","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2014.04.003_bib0335","first-page":"519","article-title":"Chagas disease (American trypanosomiasis) \u2013 factsheet (revised in August 2012)","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.pt.2014.04.003_bib0340","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1473-3099(02)00347-X","article-title":"Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda","volume":"8","author":"Guerin","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2014.04.003_bib0345","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bmb\/lds031","article-title":"Management of trypanosomiasis and leishmaniasis","volume":"104","author":"Barrett","year":"2012","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.pt.2014.04.003_bib0350","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0355","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev.mi.49.100195.002515","article-title":"Biodegradation of nitroaromatic compounds","volume":"49","author":"Spain","year":"1995","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.pt.2014.04.003_bib0360","first-page":"1078","article-title":"Nitroreductases: enzymes with environmental, biotechnological and clinical importance","volume":"Vol. 2","author":"de Oliveira","year":"2010"},{"key":"10.1016\/j.pt.2014.04.003_bib0365","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1023\/A:1015988401601","article-title":"Evidence for the involvement of a nitrenium ion in the covalent binding of nitrofurazone to DNA","volume":"5","author":"Streeter","year":"1988","journal-title":"Pharm. Res."},{"key":"10.1016\/j.pt.2014.04.003_bib0370","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1016\/S0021-9258(18)50687-6","article-title":"Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes","volume":"254","author":"Peterson","year":"1979","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2014.04.003_bib0375","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2174\/156802611795429185","article-title":"Target validation: linking target and chemical properties to desired product profile","volume":"11","author":"Wyatt","year":"2011","journal-title":"Curr. Top. Med. Chem."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492214000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492214000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:27:42Z","timestamp":1648880862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492214000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1471492214000579"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2014.04.003","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2014.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}